GB1062357A
(en)
|
1965-03-23 |
1967-03-22 |
Pfizer & Co C |
Quinazolone derivatives
|
US4032637A
(en)
|
1972-09-26 |
1977-06-28 |
Sandoz Ltd. |
Method of promoting sleep
|
US4337341A
(en)
|
1976-11-02 |
1982-06-29 |
Eli Lilly And Company |
4a-Aryl-octahydro-1H-2-pyrindines
|
GB8608335D0
(en)
|
1986-04-04 |
1986-05-08 |
Pfizer Ltd |
Pharmaceutically acceptable salts
|
US5453510A
(en)
|
1990-07-13 |
1995-09-26 |
Burroughs Wellcome Co. |
Neuromuscular blocking agents
|
JPH0741461A
(ja)
|
1993-05-27 |
1995-02-10 |
Eisai Co Ltd |
スルホン酸エステル誘導体
|
EP0813525B9
(en)
|
1995-03-10 |
2004-02-04 |
Berlex Laboratories, Inc. |
Benzamidine derivatives their preparation and their use as anti-coagulants
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9619284D0
(en)
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9622363D0
(en)
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP1054004B1
(en)
|
1997-12-15 |
2008-07-16 |
Astellas Pharma Inc. |
Novel pyrimidine-5-carboxamide derivatives
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
JP2002523497A
(ja)
|
1998-08-29 |
2002-07-30 |
アストラゼネカ・アクチエボラーグ |
ピリミジン化合物
|
CZ301367B6
(cs)
|
1998-11-10 |
2010-02-03 |
Janssen Pharmaceutica N. V. |
Derivát pyrimidinu, zpusob a meziprodukty pro jeho prípravu a lécivo pro lécení HIV na jeho bázi
|
US6262088B1
(en)
|
1998-11-19 |
2001-07-17 |
Berlex Laboratories, Inc. |
Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
|
US6127376A
(en)
|
1998-12-04 |
2000-10-03 |
Berlex Laboratories, Inc. |
Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
AU2871900A
(en)
|
1999-02-04 |
2000-08-25 |
Millennium Pharmaceuticals, Inc. |
G-protein coupled heptahelical receptor binding compounds and methods of use thereof
|
GB9914258D0
(en)
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DE60004671T2
(de)
|
1999-06-29 |
2004-07-29 |
EGIS Gyógyszergyár Rt. |
Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
|
IL150420A0
(en)
|
1999-12-28 |
2002-12-01 |
Pharmacopeia Inc |
Pyrimidine and triazine kinase inhibitors
|
HUP0301117A3
(en)
|
2000-02-17 |
2004-01-28 |
Amgen Inc Thousand Oaks |
Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
EP1282607B1
(en)
|
2000-05-08 |
2015-11-11 |
Janssen Pharmaceutica NV |
Prodrugs of hiv replication inhibiting pyrimidines
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
CA2417500C
(en)
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
US6908906B2
(en)
*
|
2001-02-09 |
2005-06-21 |
Sankyo Company, Limited |
Crystalline forms of pyrimidine nucleoside derivative
|
US6881737B2
(en)
|
2001-04-11 |
2005-04-19 |
Amgen Inc. |
Substituted triazinyl acrylamide derivatives and methods of use
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
CA2463822A1
(en)
|
2001-11-01 |
2003-05-08 |
Janssen Pharmaceutica N.V. |
Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
CA2476281A1
(en)
|
2002-02-08 |
2003-08-14 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
CA2478981A1
(en)
|
2002-03-21 |
2003-10-02 |
Sunesis Pharmaceuticals, Inc. |
Identification of kinase inhibitors
|
US20040002395A1
(en)
|
2002-06-27 |
2004-01-01 |
Poynor Raymond L. |
Bridge weight for metal wood golf club
|
CN103169708B
(zh)
|
2002-07-29 |
2018-02-02 |
里格尔药品股份有限公司 |
用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
|
CA2439440A1
(en)
|
2002-09-05 |
2004-03-05 |
Emory University |
Treatment of tuberous sclerosis associated neoplasms
|
AU2002951853A0
(en)
|
2002-10-04 |
2002-10-24 |
Commonwealth Scientific And Industrial Research Organisation |
Crystal structure of erbb2 and uses thereof
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
KR20110132482A
(ko)
|
2003-02-07 |
2011-12-07 |
얀센 파마슈티카 엔.브이. |
Hiv 감염 예방용 피리미딘 유도체
|
DE602004021472D1
(en)
|
2003-02-20 |
2009-07-23 |
Smithkline Beecham Corp |
Pyrimiidinverbindungen
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
RS53109B
(en)
|
2003-07-30 |
2014-06-30 |
Rigel Pharmaceuticals Inc. |
2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
|
DK1663242T3
(da)
|
2003-08-07 |
2011-08-01 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
|
DK1660458T3
(da)
|
2003-08-15 |
2012-05-07 |
Irm Llc |
2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
|
GB0321710D0
(en)
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
EP1663992A1
(en)
|
2003-09-18 |
2006-06-07 |
Novartis AG |
2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
|
US7511137B2
(en)
|
2003-12-19 |
2009-03-31 |
Rigel Pharmaceuticals, Inc. |
Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
|
GB2424882B
(en)
|
2004-01-12 |
2008-08-06 |
Cytopia Res Pty Ltd |
Selective kinase inhibitors
|
SG149817A1
(en)
|
2004-01-16 |
2009-02-27 |
Wyeth Corp |
Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
|
EP1735268B1
(en)
|
2004-03-15 |
2012-02-15 |
Eli Lilly And Company |
Opioid receptor antagonists
|
WO2005105988A2
(en)
|
2004-04-28 |
2005-11-10 |
Vertex Pharmaceuticals Incorporated |
Crystal structure of human jak3 kinase domain complex and binding pockets thereof
|
CA2566531A1
(en)
|
2004-05-18 |
2005-12-15 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
EP1598343A1
(de)
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
WO2005118876A2
(en)
|
2004-06-04 |
2005-12-15 |
Genentech, Inc. |
Egfr mutations
|
US7521457B2
(en)
|
2004-08-20 |
2009-04-21 |
Boehringer Ingelheim International Gmbh |
Pyrimidines as PLK inhibitors
|
GB0419161D0
(en)
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
EP1805142A4
(en)
|
2004-09-23 |
2009-06-10 |
Reddy Us Therapeutics Inc |
PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
|
US7531548B2
(en)
|
2004-09-30 |
2009-05-12 |
Tibotec Pharmaceuticals Ltd |
HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
|
PA8649401A1
(es)
|
2004-10-13 |
2006-09-22 |
Wyeth Corp |
Analogos de anilino-pirimidina
|
WO2006045066A2
(en)
|
2004-10-20 |
2006-04-27 |
Proteolix, Inc. |
Labeled compounds for proteasome inhibition
|
TW200628463A
(en)
|
2004-11-10 |
2006-08-16 |
Synta Pharmaceuticals Corp |
Heteroaryl compounds
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
ATE540035T1
(de)
|
2004-11-24 |
2012-01-15 |
Rigel Pharmaceuticals Inc |
Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
MY169441A
(en)
|
2004-12-08 |
2019-04-11 |
Janssen Pharmaceutica Nv |
2,4, (4,6) pyrimidine derivatives
|
ATE519759T1
(de)
|
2004-12-30 |
2011-08-15 |
Exelixis Inc |
Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
|
CA2594860A1
(en)
|
2005-01-14 |
2006-07-20 |
Millennium Pharmaceuticals, Inc. |
Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
|
ES2337496T3
(es)
|
2005-01-19 |
2010-04-26 |
Rigel Pharmaceuticals, Inc. |
Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
|
CN101193905B
(zh)
|
2005-02-11 |
2014-06-25 |
纪念斯隆-凯特林癌症中心 |
用于检测抗药egfr突变体的方法和组合物
|
KR20070113288A
(ko)
|
2005-03-16 |
2007-11-28 |
탈자진 인코포레이티드 |
피리미딘 화합물 및 사용 방법
|
DE102005016634A1
(de)
|
2005-04-12 |
2006-10-19 |
Merck Patent Gmbh |
Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
|
CA2604551A1
(en)
|
2005-05-03 |
2007-03-08 |
Rigel Pharmaceuticals, Inc. |
Jak kinase inhibitors and their uses
|
WO2006124874A2
(en)
|
2005-05-12 |
2006-11-23 |
Kalypsys, Inc. |
Inhibitors of b-raf kinase
|
WO2006128129A2
(en)
|
2005-05-26 |
2006-11-30 |
Synta Pharmaceuticals Corp. |
Method for treating cancer
|
WO2006128172A2
(en)
|
2005-05-26 |
2006-11-30 |
Synta Pharmaceuticals Corp. |
Method for treating b cell regulated autoimmune disorders
|
WO2006129100A1
(en)
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Novel compounds
|
NZ563454A
(en)
|
2005-06-08 |
2011-03-31 |
Rigel Pharmaceuticals Inc |
2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2007048065A2
(en)
|
2005-10-21 |
2007-04-26 |
Exelixis, Inc. |
Pyrimidinones as casein kinase ii (ck2) modulators
|
NZ592990A
(en)
|
2005-11-01 |
2013-01-25 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
KR20080053954A
(ko)
|
2005-11-03 |
2008-06-16 |
아이알엠 엘엘씨 |
단백질 키나제 억제제
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
US20080318989A1
(en)
|
2005-12-19 |
2008-12-25 |
Burdick Daniel J |
Pyrimidine Kinase Inhibitors
|
TW200736232A
(en)
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
KR20080110998A
(ko)
|
2006-01-30 |
2008-12-22 |
엑셀리시스, 인코포레이티드 |
Jak2 조절자로서 4아릴2아미노피리미딘 또는 4아릴2아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물
|
CA2642211C
(en)
|
2006-02-17 |
2012-01-24 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
|
EP1991532B1
(en)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
EP2004632B1
(en)
|
2006-03-30 |
2014-03-12 |
Janssen R&D Ireland |
Hiv inhibiting 5-amido substituted pyrimidines
|
DK2004641T3
(da)
|
2006-03-30 |
2011-01-24 |
Tibotec Pharm Ltd |
HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
|
CA2861601A1
(en)
|
2006-04-27 |
2007-11-08 |
Intezyne Technologies, Inc. |
Poly (ethylene glycol) containing chemically disparate endgroups
|
GB0608386D0
(en)
|
2006-04-27 |
2006-06-07 |
Senexis Ltd |
Compounds
|
DE102006027156A1
(de)
|
2006-06-08 |
2007-12-13 |
Bayer Schering Pharma Ag |
Sulfimide als Proteinkinaseinhibitoren
|
CA2656290A1
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
JP2009544592A
(ja)
|
2006-07-21 |
2009-12-17 |
ノバルティス アクチエンゲゼルシャフト |
Jakキナーゼ阻害剤としての2,4−ジ(アリールアミノ)−ピリミジン−5−カルボキサミド化合物
|
DE102006041382A1
(de)
|
2006-08-29 |
2008-03-20 |
Bayer Schering Pharma Ag |
Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
|
CN102887900B
(zh)
|
2006-09-22 |
2015-04-29 |
药品循环公司 |
布鲁顿酪氨酸激酶的抑制剂
|
CA2673125C
(en)
|
2006-10-19 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
ES2403546T3
(es)
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
ES2380551T3
(es)
|
2006-11-21 |
2012-05-16 |
Rigel Pharmaceuticals, Inc. |
Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
|
AU2007333394C1
(en)
|
2006-12-08 |
2011-08-18 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
US20100144732A1
(en)
|
2006-12-19 |
2010-06-10 |
Krueger Elaine B |
Pyrimidine kinase inhibitors
|
EP1939185A1
(de)
|
2006-12-20 |
2008-07-02 |
Bayer Schering Pharma Aktiengesellschaft |
Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
|
JP5185283B2
(ja)
|
2006-12-29 |
2013-04-17 |
テイボテク・フアーマシユーチカルズ |
Hiv阻害6−置換ピリミジン
|
CN101573342A
(zh)
|
2006-12-29 |
2009-11-04 |
泰博特克药品有限公司 |
抑制hiv的5,6-取代的嘧啶类化合物
|
TW200902010A
(en)
|
2007-01-26 |
2009-01-16 |
Smithkline Beecham Corp |
Anthranilamide inhibitors of aurora kinase
|
CA2702647C
(en)
|
2007-01-31 |
2016-03-22 |
Ym Biosciences Australia Pty Ltd |
Thiopyrimidine-based compounds and uses thereof
|
JP4221470B2
(ja)
|
2007-02-01 |
2009-02-12 |
トヨタ自動車株式会社 |
電動車両制御装置及び電動車両制御方法
|
DE102007010801A1
(de)
|
2007-03-02 |
2008-09-04 |
Bayer Cropscience Ag |
Diaminopyrimidine als Fungizide
|
AU2008229151A1
(en)
|
2007-03-20 |
2008-09-25 |
Smithkline Beecham Corporation |
Chemical compounds
|
CN101677554A
(zh)
|
2007-03-20 |
2010-03-24 |
史密丝克莱恩比彻姆公司 |
化合物
|
WO2008118822A1
(en)
|
2007-03-23 |
2008-10-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2008118823A2
(en)
|
2007-03-26 |
2008-10-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US8242271B2
(en)
|
2007-06-04 |
2012-08-14 |
Avila Therapeutics, Inc. |
Heterocyclic compounds and uses thereof
|
WO2009012421A1
(en)
|
2007-07-17 |
2009-01-22 |
Rigel Pharmaceuticals, Inc. |
Cyclic amine substituted pyrimidinediamines as pkc inhibitors
|
WO2009017838A2
(en)
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
JP2010538004A
(ja)
|
2007-08-28 |
2010-12-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
キナーゼ阻害剤としての2−ビフェニルアミノ−4−アミノピリミジン誘導体
|
WO2009032694A1
(en)
|
2007-08-28 |
2009-03-12 |
Dana Farber Cancer Institute |
Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
|
WO2009029682A1
(en)
|
2007-08-28 |
2009-03-05 |
Rigel Pharmaceuticals, Inc. |
Combination therapy with syk kinase inhibitor
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
CA2702674C
(en)
|
2007-10-19 |
2016-05-03 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
EP2234986A2
(en)
|
2007-12-20 |
2010-10-06 |
Cellzome Limited |
Sulfamides as zap-70 inhibitors
|
DK2252300T3
(en)
|
2008-02-22 |
2017-02-06 |
Rigel Pharmaceuticals Inc |
USE OF 2,4-PYRIMIDINE DIAMINES TO TREAT Atherosclerosis
|
US20110098288A1
(en)
|
2008-03-11 |
2011-04-28 |
Jeremy Major |
Sulfonamides as zap-70 inhibitors
|
US8205348B2
(en)
|
2008-03-19 |
2012-06-26 |
Zashiki-Warashi Manufacturing Inc. |
Tile spacer and holder therefor
|
CL2009000600A1
(es)
|
2008-03-20 |
2010-05-07 |
Bayer Cropscience Ag |
Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
|
WO2009127642A2
(en)
|
2008-04-15 |
2009-10-22 |
Cellzome Limited |
Use of lrrk2 inhibitors for neurodegenerative diseases
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
CA2722326A1
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
SI2300013T1
(en)
|
2008-05-21 |
2018-03-30 |
Adriad Pharmacaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
CA2986640C
(en)
*
|
2008-06-27 |
2019-03-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP3311818A3
(en)
|
2008-07-16 |
2018-07-18 |
Pharmacyclics, LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
US20110245284A1
(en)
|
2008-09-03 |
2011-10-06 |
Bayer Cropscience Ag |
Alkoxy- and Alkylthio-Substituted Anilinopyrimidines
|
WO2010077740A2
(en)
|
2008-12-09 |
2010-07-08 |
Cytokine Pharmasciences, Inc. |
Novel antiviral compounds, compositions, and methods of use
|
CA2748758C
(en)
|
2009-01-15 |
2017-06-13 |
F. Hoffmann-La Roche Ag |
Antibodies against phosphorylated tyrosines on erythropoietin receptor (epor)
|
CA2757671A1
(en)
|
2009-04-03 |
2010-10-07 |
Cellzome Ag |
Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
|
WO2010129053A2
(en)
|
2009-05-05 |
2010-11-11 |
Dana Farber Cancer Institute |
Egfr inhibitors and methods of treating disorders
|
MX2011011875A
(es)
|
2009-05-08 |
2011-12-08 |
Astellas Pharma Inc |
Compuesto de carboxamida heterociclica diamino.
|
CA2763720A1
(en)
|
2009-06-18 |
2010-12-23 |
Cellzome Limited |
Sulfonamides and sulfamides as zap-70 inhibitors
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
US20110207736A1
(en)
|
2009-12-23 |
2011-08-25 |
Gatekeeper Pharmaceuticals, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
US20130137709A1
(en)
|
2010-05-05 |
2013-05-30 |
Nathanael S. Gray |
Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
EA031737B1
(ru)
|
2010-06-03 |
2019-02-28 |
Фармасайкликс, Инк. |
Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
|
WO2011153553A2
(en)
|
2010-06-04 |
2011-12-08 |
The Regents Of The University Of California |
Methods and compositions for kinase inhibition
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
WO2012061415A1
(en)
|
2010-11-01 |
2012-05-10 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
MX2013004894A
(es)
*
|
2010-11-01 |
2013-10-17 |
Celgene Avilomics Res Inc |
Compuestos heterociclicos y usos de los mismos.
|
US9238629B2
(en)
|
2010-11-01 |
2016-01-19 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
EP2637502B1
(en)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
DK2710007T3
(da)
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
Kinasehæmmere
|
US9108927B2
(en)
|
2012-03-15 |
2015-08-18 |
Celgene Avilomics Research, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
CA2866852C
(en)
|
2012-03-15 |
2020-12-29 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
CA2890111A1
(en)
|
2012-11-02 |
2014-05-08 |
Pharmacyclics, Inc. |
Tec family kinase inhibitor adjuvant therapy
|
US20160074399A1
(en)
|
2013-05-06 |
2016-03-17 |
Clovis Oncology, Inc. |
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
|